Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Atea Pharmaceuticals, Inc. (AVIR)
USD4.82
+0.12 (+2.45%)
US NASDAQ Healthcare Biotechnology
Address
225 Franklin Street 2110
Boston, MA, US
Boston, MA, US
CEO
Jean-Pierre Sommadossi
Website
ateapharma.com
IPO
2020-10-30
CIK 1593899 ISIN US04683R1068
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.82
+0.12 (+2.45%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
328.4K
Beta
0.32
Float Shares
59.97M
Free Float %
75.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -16.91% | -17.06% | -19.96% | +6.03% | +49.35% | +28.01% | +73.76% | +32.46% | -76.22% | -84.94% | -84.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Hold
Price Targets & DCF
Current price
4.82
Low
10.00
+107.7%
Consensus
10.00
+107.7%
Median
10.00
+107.7%
High
10.00
+107.7%
DCF (Unlevered)
1.01
-78.9%
DCF (Levered)
1.16
-75.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
10.00
+107.7%
|
| Last Year | 1 |
10.00
+107.7%
|
| All Time | 2 |
8.44
+75.3%
|
Quality scores
Altman Z-Score
3.63
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+3.0% Q1'26: -42.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-3.3% ★ Q1'26: -7.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
48.63M
est: 163.00M (-70.2%)
|
351.37M
est: 258.98M (+35.7%)
|
—
est: 240.98M (-100.0%)
|
—
est: 68.29M (-100.0%)
|
—
est: 7.08M (-100.0%)
|
5.74M
5.74M – 5.74M
-18.9% YoY
|
30.46M
30.46M – 30.46M
+430.5% YoY
|
71.29M
71.29M – 71.29M
+134.0% YoY
|
| EBITDA |
-11.01M
est: 103.26M (-110.7%)
|
138.41M
est: 164.07M (-15.6%)
|
-110.84M
est: 152.66M (-172.6%)
|
-131.80M
est: 60.01M (-319.6%)
|
-180.47M
est: 6.22M (-3,000.7%)
|
5.05M
5.05M – 5.05M
-18.9% YoY
|
26.77M
26.77M – 26.77M
+430.5% YoY
|
62.64M
62.64M – 62.64M
+134.0% YoY
|
| EBIT |
-11.03M
est: 103.24M (-110.7%)
|
138.38M
est: 164.04M (-15.6%)
|
-111.10M
est: 152.64M (-172.8%)
|
-132.22M
est: 60.01M (-320.3%)
|
-180.89M
est: 6.22M (-3,007.4%)
|
5.05M
5.05M – 5.05M
-18.9% YoY
|
26.77M
26.77M – 26.77M
+430.5% YoY
|
62.64M
62.64M – 62.64M
+134.0% YoY
|
| Net Income |
-10.95M
est: 144.65M (-107.6%)
|
121.19M
est: 743.25M (-83.7%)
|
-115.91M
est: -106.15M (-9.2%)
|
-168.39M
est: -148.13M (-13.7%)
|
-158.35M
est: -140.17M (-13.0%)
|
-170.00M
-189.65M – -124.93M
-21.3% YoY
|
-112.87M
-122.46M – -103.28M
+33.6% YoY
|
-78.24M
-78.24M – -78.24M
+30.7% YoY
|
| SGA |
21.64M
est: 116.55M (-81.4%)
|
45.79M
est: 203.85M (-77.5%)
|
48.71M
est: 166.37M (-70.7%)
|
48.85M
est: 56.41M (-13.4%)
|
32.86M
est: 5.85M (+461.9%)
|
4.74M
4.74M – 4.74M
-18.9% YoY
|
25.16M
25.16M – 25.16M
+430.5% YoY
|
58.89M
58.89M – 58.89M
+134.0% YoY
|
| EPS |
-0.13
est: 1.72 (-107.6%)
|
1.46
est: 0.45 (+222.8%)
|
-1.39
est: -1.31 (-6.2%)
|
-2.00
est: -1.80 (-10.9%)
|
-1.94
est: -1.73 (-12.5%)
|
-1.93
-2.33 – -1.53
-11.9% YoY
|
-1.39
-1.50 – -1.27
+28.2% YoY
|
-0.96
-0.96 – -0.96
+30.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-132.03M
OE per share TTM
-1.62
Owner's Yield
-31.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
26
Total invested
9.78M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 6.62M | 7.84% | — | — | 6.62M | — | IN | Delaware | 2024-11-12 | ↗ |
| 2 | FMR LLC | 6.62M | 7.84% | 6.61M | — | 6.62M | — | HC | Delaware | 2024-11-12 | ↗ |
| 3 | Braden M Leonard | 5.60M | 6.70% | 140.0K | 5.46M | 140.0K | 5.46M | IN | — | 2024-02-07 | ↗ |
| 4 | BML Investment Partners, L.P. | 5.46M | 6.50% | — | 5.46M | — | 5.46M | PN | — | 2024-02-07 | ↗ |
| 5 | KEVIN TANG | 3.03M | 3.60% | — | 3.03M | — | 3.03M | IN | — | 2023-05-22 | ↗ |
| 6 | TANG CAPITAL MANAGEMENT, LLC | 3.03M | 3.60% | — | 3.03M | — | 3.03M | OO | DELAWARE | 2023-05-22 | ↗ |
| 7 | TANG CAPITAL PARTNERS, LP | 3.03M | 3.60% | — | 3.03M | — | 3.03M | PN | — | 2023-05-22 | ↗ |
| 8 | Bihua Chen | 1.68M | 2.02% | — | 1.68M | — | — | IN | United States | 2022-02-14 | ↗ |
| 9 | Cormorant Asset Management, LP | 1.68M | 2.02% | — | 1.68M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 10 | Cormorant Private Healthcare Fund I, LP | 1.25M | 1.50% | — | 1.25M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 11 | Cormorant Private Healthcare GP, LLC | 1.25M | 1.50% | — | 1.25M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 12 | Cormorant Global Healthcare GP, LLC | 300.0K | 0.36% | — | 300.0K | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 13 | Cormorant Global Healthcare Master Fund, LP | 300.0K | 0.36% | — | 300.0K | — | — | PN | Cayman Islands | 2022-02-14 | ↗ |
| 14 | Biosciences, LLC | — | 0.00% | — | — | — | — | OO | — | 2023-05-22 | ↗ |
| 15 | Cheung Ka Ho | — | 0.00% | — | — | — | — | IN | Hong Kong | 2022-02-16 | ↗ |
| 16 | Cormorant Private Healthcare Fund II, LP | — | 0.00% | — | — | — | — | PN | — | 2022-02-14 | ↗ |
| 17 | Cormorant Private Healthcare GP II, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 18 | Frances Anne Elizabeth Richard | — | 0.00% | — | — | — | — | IN | — | 2022-02-16 | ↗ |
| 19 | Jill Marie Franklin | — | 0.00% | — | — | — | — | IN | United Kingdom | 2022-02-16 | ↗ |
| 20 | Morningside Venture Investments Ltd | — | 0.00% | — | — | — | — | CO | British Virgin Islands | 2022-02-16 | ↗ |
| 21 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2022-02-14 | ↗ |
| 22 | Peter Stuart Allenby Edwards | — | 0.00% | — | — | — | — | IN | United Kingdom | 2022-02-16 | ↗ |
| 23 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 24 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 25 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
26
-85 vs prev Q
New positions
2
Closed positions
87
Increased
8
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 70.0K +70.0K (+100.0%) | 250.00M +250.0M (+100.0%) | 0.09% +0.089 pp | 0.00% +0.000 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 2 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 50.0K +50.0K (+100.0%) | 178.50M +178.5M (+100.0%) | 0.06% +0.063 pp | 0.15% +0.152 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 3 | FMR LLC | 9.68M +3.9M (+66.2%) | 34.55M +17.7M (+104.6%) | 12.24% +5.291 pp | 0.00% +0.001 pp | USD23.60 -84.9% | 21 qtrs — |
| 4 | BLACKROCK, INC. | 8.49M +32.0K (+0.4%) | 30.31M +5.8M (+23.6%) | 10.74% +0.640 pp | 0.00% +0.000 pp | USD3.35 +6.6% | 6 qtrs — |
| 5 | BML CAPITAL MANAGEMENT, LLC | 7.49M +16.0K (+0.2%) | 26.74M +5.1M (+23.4%) | 9.47% +0.550 pp | 23.11% +3.267 pp | USD3.33 +7.2% | 11 qtrs — |
| 6 | TANG CAPITAL MANAGEMENT LLC | 4.81M -11.5K (-0.2%) | 17.19M +3.2M (+22.8%) | 6.09% +0.328 pp | 0.85% +0.310 pp | USD3.45 +3.5% | 12 qtrs — |
| 7 | VANGUARD GROUP INC | 4.23M -482.2K (-10.2%) | 15.09M +1.4M (+10.5%) | 5.35% -0.276 pp | 0.00% +0.000 pp | USD19.22 -81.4% | 21 qtrs — |
| 8 | BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 2.49M +— (+0.0%) | 8.87M +1.7M (+23.1%) | 3.14% +0.176 pp | 0.68% +0.201 pp | USD41.78 -91.5% | 21 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.84M -58.7K (-3.1%) | 6.57M +1.1M (+19.3%) | 2.33% +0.060 pp | 0.00% +0.000 pp | USD17.46 -79.6% | 21 qtrs — |
| 10 | STATE STREET CORP | 1.78M +491.0 (+0.0%) | 6.37M +1.2M (+23.1%) | 2.26% +0.127 pp | 0.00% +0.000 pp | USD15.44 -76.9% | 21 qtrs — |
| 11 | DIMENSIONAL FUND ADVISORS LP | 1.37M -166.8K (-10.8%) | 4.90M +436.7K (+9.8%) | 1.74% -0.102 pp | 0.00% +0.000 pp | USD3.43 +4.1% | 12 qtrs — |
| 12 | JPMORGAN CHASE & CO | 1.35M +731.4K (+118.6%) | 4.81M +3.0M (+169.1%) | 1.71% +0.969 pp | 0.00% +0.000 pp | USD3.46 +3.2% | 21 qtrs — |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 1.30M +334.1K (+34.5%) | 4.65M +1.8M (+65.5%) | 1.65% +0.491 pp | 0.01% +0.003 pp | USD5.80 -38.4% | 19 qtrs — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 1.19M -39.4K (-3.2%) | 4.24M +682.0K (+19.2%) | 1.50% +0.037 pp | 0.01% +0.002 pp | USD5.32 -32.9% | 18 qtrs — |
| 15 | TWO SIGMA ADVISERS, LP | 1.06M +263.5K (+33.1%) | 3.78M +1.5M (+63.8%) | 1.34% +0.390 pp | 0.01% +0.003 pp | USD3.46 +3.2% | 11 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 745.4K +274.1K (+58.2%) | 2.66M +1.3M (+94.7%) | 0.94% +0.380 pp | 0.00% +0.002 pp | USD3.52 +1.4% | 11 qtrs — |
| 17 | MILLENNIUM MANAGEMENT LLC | 698.2K +210.9K (+43.3%) | 2.49M +1.1M (+76.4%) | 0.88% +0.301 pp | 0.00% +0.000 pp | USD3.22 +10.9% | 5 qtrs — |
| 18 | MORGAN STANLEY | 656.1K +205.5K (+45.6%) | 2.34M +1.0M (+79.3%) | 0.83% +0.292 pp | 0.00% +0.000 pp | USD6.20 -42.4% | 21 qtrs — |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 607.8K -17.2K (-2.8%) | 2.17M +357.4K (+19.7%) | 0.77% +0.023 pp | 0.00% +0.000 pp | USD19.43 -81.6% | 21 qtrs — |
| 20 | NORTHERN TRUST CORP | 560.2K -78.2K (-12.2%) | 2.00M +148.7K (+8.0%) | 0.71% -0.054 pp | 0.00% +0.000 pp | USD20.79 -82.8% | 21 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 472.5K +132.4K (+38.9%) | 1.69M +700.5K (+71.0%) | 0.60% +0.192 pp | 0.00% +0.000 pp | USD11.23 -68.2% | 21 qtrs — |
| 22 | D. E. SHAW & CO., INC. | 464.8K +100.0K (+27.4%) | 1.66M +601.5K (+56.9%) | 0.59% +0.152 pp | 0.00% +0.000 pp | USD3.25 +9.8% | 14 qtrs — |
| 23 | PEAPOD LANE CAPITAL LLC | 435.0K -22.2K (-4.9%) | 1.55M +227.1K (+17.1%) | 0.55% +0.004 pp | 1.32% +0.135 pp | USD3.25 +9.8% | 5 qtrs — |
| 24 | CM MANAGEMENT, LLC | 355.0K -145.0K (-29.0%) | 1.27M -182.7K (-12.6%) | 0.45% -0.148 pp | 1.07% -0.141 pp | USD6.95 -48.6% | 19 qtrs — |
| 25 | BANQUE PICTET & CIE SA | 345.1K +— (+0.0%) | 1.23M +231.2K (+23.1%) | 0.44% +0.025 pp | 0.01% +0.001 pp | USD19.15 -81.4% | 19 qtrs — |
| 26 | JANE STREET GROUP, LLC | 250.7K +58.6K (+30.5%) | 895.0K +337.9K (+60.7%) | 0.32% +0.088 pp | 0.00% +0.000 pp | USD3.16 +13.0% | 19 qtrs — |
| 27 | BARCLAYS PLC | 243.0K +65.9K (+37.2%) | 867.5K +274.3K (+46.2%) | 0.31% +0.096 pp | 0.00% +0.000 pp | USD3.45 +3.5% | 16 qtrs — |
| 28 | WELLINGTON MANAGEMENT GROUP LLP | 242.8K -19.9K (-7.6%) | 866.9K +104.9K (+13.8%) | 0.31% -0.007 pp | 0.00% +0.000 pp | USD3.70 -3.5% | 8 qtrs — |
| 29 | NUVEEN, LLC | 240.6K -15.3K (-6.0%) | 858.9K +116.9K (+15.8%) | 0.30% -0.001 pp | 0.00% +0.000 pp | USD2.99 +19.4% | 4 qtrs — |
| 30 | HSBC HOLDINGS PLC | 241.3K +34.9K (+16.9%) | 855.3K +265.1K (+44.9%) | 0.31% +0.059 pp | 0.00% +0.000 pp | USD3.11 +14.8% | 10 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 198.5K -9.0K (-4.3%) | 708.5K +106.8K (+17.8%) | 0.25% +0.003 pp | 0.00% +0.000 pp | USD20.63 -82.7% | 21 qtrs — |
| 32 | UBS GROUP AG | 192.5K +90.3K (+88.4%) | 687.4K +391.0K (+131.9%) | 0.24% +0.122 pp | 0.00% +0.000 pp | USD3.76 -5.1% | 21 qtrs — |
| 33 | OPALEYE MANAGEMENT INC. | 179.8K +179.8K (+100.0%) | 641.9K +641.9K (+100.0%) | 0.23% +0.228 pp | 0.08% +0.085 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 34 | AUOUR INVESTMENTS LLC | 177.0K +— (+0.0%) | 631.9K +118.6K (+23.1%) | 0.22% +0.013 pp | 0.20% +0.034 pp | USD3.74 -4.5% | 11 qtrs — |
| 35 | AMERICAN CENTURY COMPANIES INC | 170.3K -11.4K (-6.3%) | 608.1K +81.2K (+15.4%) | 0.22% -0.002 pp | 0.00% +0.000 pp | USD5.63 -36.6% | 18 qtrs — |
| 36 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 148.4K +5.3K (+3.7%) | 529.8K +114.8K (+27.7%) | 0.19% +0.017 pp | 0.01% +0.002 pp | USD3.09 +15.5% | 5 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 135.8K -177.9K (-56.7%) | 484.8K -424.8K (-46.7%) | 0.17% -0.203 pp | 0.00% +0.000 pp | USD3.33 +7.2% | 21 qtrs — |
| 38 | ALLIANCEBERNSTEIN L.P. | 127.8K +— (+0.0%) | 456.3K +85.6K (+23.1%) | 0.16% +0.009 pp | 0.00% +0.000 pp | USD17.70 -79.8% | 21 qtrs — |
| 39 | MARSHALL WACE, LLP | 113.6K +26.5K (+30.5%) | 405.5K +153.0K (+60.6%) | 0.14% +0.040 pp | 0.00% +0.000 pp | USD3.21 +11.2% | 7 qtrs — |
| 40 | STRS OHIO | 113.5K +— (+0.0%) | 405.2K +76.0K (+23.1%) | 0.14% +0.008 pp | 0.00% +0.000 pp | USD10.04 -64.4% | 21 qtrs — |
| 41 | PRICE T ROWE ASSOCIATES INC /MD/ | 97.3K -213.0 (-0.2%) | 348.0K +65.0K (+23.0%) | 0.12% +0.007 pp | 0.00% +0.000 pp | USD11.92 -70.1% | 21 qtrs — |
| 42 | RHUMBLINE ADVISERS | 94.0K -19.6K (-17.3%) | 335.5K +6.0K (+1.8%) | 0.12% -0.017 pp | 0.00% +0.000 pp | USD16.45 -78.3% | 21 qtrs — |
| 43 | STATE OF WISCONSIN INVESTMENT BOARD | 91.2K -15.7K (-14.7%) | 325.7K +15.5K (+5.0%) | 0.12% -0.012 pp | 0.00% +0.000 pp | USD11.20 -68.1% | 21 qtrs — |
| 44 | ALDEBARAN CAPITAL, LLC | 90.5K +90.5K (+100.0%) | 323.2K +323.2K (+100.0%) | 0.11% +0.115 pp | 0.29% +0.290 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 45 | INVESCO LTD. | 87.9K -36.5K (-29.3%) | 313.8K -46.9K (-13.0%) | 0.11% -0.037 pp | 0.00% +0.000 pp | USD9.37 -61.9% | 20 qtrs — |
| 46 | RANGELEY CAPITAL, LLC | 80.0K +— (+0.0%) | 285.6K +53.6K (+23.1%) | 0.10% +0.006 pp | 0.24% +0.036 pp | USD3.36 +6.3% | 3 qtrs — |
| 47 | WELLS FARGO & COMPANY/MN | 79.8K +20.9K (+35.5%) | 284.9K +114.1K (+66.8%) | 0.10% +0.031 pp | 0.00% +0.000 pp | USD3.55 +0.6% | 21 qtrs — |
| 48 | LOS ANGELES CAPITAL MANAGEMENT LLC | 77.3K +— (+0.0%) | 252.8K +28.6K (+12.8%) | 0.10% +0.006 pp | 0.00% +0.000 pp | USD3.21 +11.2% | 3 qtrs — |
| 49 | ALPS ADVISORS INC | 64.2K +27.4K (+74.6%) | 229.0K +122.5K (+114.9%) | 0.08% +0.037 pp | 0.00% +0.001 pp | USD3.59 -0.6% | 3 qtrs — |
| 50 | POINT72 ASSET MANAGEMENT, L.P. | 63.9K +63.9K (+100.0%) | 228.1K +228.1K (+100.0%) | 0.08% +0.081 pp | 0.00% +0.000 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 51 | EVERSOURCE WEALTH ADVISORS, LLC | 57.0K -93.9K (-62.2%) | 203.4K -234.1K (-53.5%) | 0.07% -0.108 pp | 0.01% -0.010 pp | USD3.34 +6.9% | 7 qtrs — |
| 52 | DEUTSCHE BANK AG\ | 52.7K +52.7K (+100.0%) | 188.2K +188.2K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD3.57 +0.0% | 21 qtrs — |
| 53 | HRT FINANCIAL LP | 47.9K +29.0K (+154.2%) | 170.0K +116.0K (+214.8%) | 0.06% +0.038 pp | 0.00% +0.000 pp | USD3.31 +7.9% | 2 qtrs — |
| 54 | SCHONFELD STRATEGIC ADVISORS LLC | 45.9K +45.9K (+100.0%) | 163.9K +163.9K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.001 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 55 | JACOBS LEVY EQUITY MANAGEMENT, INC | 43.1K -355.3K (-89.2%) | 153.9K -1.0M (-86.7%) | 0.05% -0.421 pp | 0.00% -0.004 pp | USD3.99 -10.5% | 16 qtrs — |
| 56 | CITADEL ADVISORS LLC | 42.7K +962.0 (+2.3%) | 152.4K +31.4K (+25.9%) | 0.05% +0.004 pp | 0.00% +0.000 pp | USD2.92 +22.3% | 21 qtrs — |
| 57 | INTECH INVESTMENT MANAGEMENT LLC | 33.2K +— (+0.0%) | 118.6K +22.3K (+23.1%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD3.28 +8.8% | 6 qtrs — |
| 58 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 33.0K -3.0K (-8.3%) | 117.7K +13.4K (+12.8%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD3.35 +6.6% | 7 qtrs — |
| 59 | RBF CAPITAL, LLC | 30.0K +— (+0.0%) | 107.1K +20.1K (+23.1%) | 0.04% +0.002 pp | 0.00% +0.001 pp | USD4.81 -25.8% | 13 qtrs — |
| 60 | METLIFE INVESTMENT MANAGEMENT, LLC | 29.7K -16.2K (-35.3%) | 106.1K -27.1K (-20.4%) | 0.04% -0.017 pp | 0.00% 0.000 pp | USD12.33 -71.0% | 21 qtrs — |
| 61 | CERTIFIED ADVISORY CORP | 24.5K +— (+0.0%) | 87.5K +16.4K (+23.1%) | 0.03% +0.002 pp | 0.01% +0.001 pp | USD2.90 +23.1% | 2 qtrs — |
| 62 | BNP PARIBAS ARBITRAGE, SNC | 24.1K +4.2K (+21.2%) | 86.2K +28.4K (+49.2%) | 0.03% +0.007 pp | 0.00% +0.000 pp | USD3.25 +9.8% | 5 qtrs — |
| 63 | CREATIVE PLANNING | 24.1K +21.0 (+0.1%) | 86.0K +16.2K (+23.2%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD3.32 +7.5% | 5 qtrs — |
| 64 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 24.0K -6.1K (-20.4%) | 85.6K -1.7K (-2.0%) | 0.03% -0.006 pp | 0.00% +0.000 pp | USD27.59 -87.1% | 21 qtrs — |
| 65 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 22.0K +— (+0.0%) | 78.6K +14.7K (+23.1%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD3.37 +5.9% | 11 qtrs — |
| 66 | SQUAREPOINT OPS LLC | 19.3K +19.3K (+100.0%) | 68.9K +68.9K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 67 | JUMP FINANCIAL, LLC | 19.1K +5.1K (+36.5%) | 68.2K +27.6K (+68.0%) | 0.02% +0.008 pp | 0.00% +0.000 pp | USD3.08 +15.9% | 2 qtrs — |
| 68 | JOHNSON INVESTMENT COUNSEL INC | 18.3K +— (+0.0%) | 65.5K +12.3K (+23.1%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD3.49 +2.3% | 3 qtrs — |
| 69 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 17.2K -32.5K (-65.5%) | 61.2K -82.9K (-57.5%) | 0.02% -0.038 pp | 0.00% +0.000 pp | USD3.55 +0.6% | 19 qtrs — |
| 70 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 16.9K +— (+0.0%) | 60.5K +11.3K (+23.1%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD3.35 +6.6% | 5 qtrs — |
| 71 | VOYA INVESTMENT MANAGEMENT LLC | 16.4K +— (+0.0%) | 58.7K +11.0K (+23.1%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD12.90 -72.3% | 21 qtrs — |
| 72 | PROSHARE ADVISORS LLC | 16.4K +506.0 (+3.2%) | 58.7K +12.5K (+27.0%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD8.44 -57.7% | 20 qtrs — |
| 73 | NEW YORK STATE COMMON RETIREMENT FUND | 16.3K +— (+0.0%) | 58.4K +11.0K (+23.1%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD24.08 -85.2% | 21 qtrs — |
| 74 | RFG ADVISORY, LLC | 14.9K +14.9K (+100.0%) | 53.1K +53.1K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.001 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 75 | RUSSELL INVESTMENTS GROUP, LTD. | 14.7K +1.5K (+11.0%) | 52.4K +14.1K (+36.7%) | 0.02% +0.003 pp | 0.00% +0.000 pp | USD3.08 +15.9% | 19 qtrs — |
| 76 | AQR CAPITAL MANAGEMENT LLC | 14.3K +888.0 (+6.6%) | 51.0K +12.2K (+31.3%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD2.94 +21.4% | 2 qtrs — |
| 77 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 12.7K -1.2K (-8.5%) | 45.5K +5.1K (+12.7%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD3.47 +2.9% | 14 qtrs — |
| 78 | GRAHAM CAPITAL MANAGEMENT, L.P. | 12.7K -57.3K (-81.9%) | 45.3K -157.7K (-77.7%) | 0.02% -0.068 pp | 0.00% -0.002 pp | USD3.07 +16.3% | 5 qtrs — |
| 79 | SUNPOINTE, LLC | 11.9K +— (+0.0%) | 42.6K +8.0K (+23.1%) | 0.02% +0.001 pp | 0.01% +0.002 pp | USD3.05 +17.0% | 9 qtrs — |
| 80 | GROUP ONE TRADING, L.P. | 10.8K -133.4K (-92.5%) | 38.5K -379.7K (-90.8%) | 0.01% -0.159 pp | 0.00% -0.001 pp | USD2.92 +22.3% | 8 qtrs — |
| 81 | SG AMERICAS SECURITIES, LLC | 10.7K -9.7K (-47.5%) | 38.0K -21.0K (-35.6%) | 0.01% -0.011 pp | 0.00% 0.000 pp | USD2.90 +23.1% | 20 qtrs — |
| 82 | XTX TOPCO LTD | 10.4K -11.8K (-53.1%) | 37.3K -27.3K (-42.3%) | 0.01% -0.013 pp | 0.00% -0.002 pp | USD3.60 -0.8% | 3 qtrs — |
| 83 | RONALD BLUE TRUST, INC. | 8.7K +— (+0.0%) | 31.1K +5.8K (+23.1%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD7.10 -49.7% | 15 qtrs — |
| 84 | AMERITAS INVESTMENT PARTNERS, INC. | 7.5K +— (+0.0%) | 26.8K +5.0K (+23.1%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD18.75 -81.0% | 21 qtrs — |
| 85 | LEGAL & GENERAL GROUP PLC | 5.9K -1.3K (-17.8%) | 21.2K +255.0 (+1.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD14.12 -74.7% | 21 qtrs — |
| 86 | FNY INVESTMENT ADVISERS, LLC | 5.0K +— (+0.0%) | 17.0K +3.0K (+21.4%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.99 +19.4% | 4 qtrs — |
| 87 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 4.4K -404.0 (-8.5%) | 15.6K +1.8K (+12.7%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD2.90 +23.1% | 21 qtrs — |
| 88 | STERLING CAPITAL MANAGEMENT LLC | 4.1K -1.2K (-22.5%) | 14.6K -712.0 (-4.6%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD3.13 +14.1% | 6 qtrs — |
| 89 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 3.8K +728.0 (+23.7%) | 13.6K +4.7K (+52.3%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.79 -5.8% | 15 qtrs — |
| 90 | CITIGROUP INC | 3.8K -4.9K (-56.3%) | 13.5K -11.6K (-46.2%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD3.34 +6.9% | 21 qtrs — |
| 91 | SMARTLEAF ASSET MANAGEMENT LLC | 3.3K +3.3K (+100.0%) | 11.7K +11.7K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD3.57 +0.0% | 1 qtrs NEW |
| 92 | PNC FINANCIAL SERVICES GROUP, INC. | 2.8K -906.0 (-24.2%) | 10.2K -721.0 (-6.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.48 +2.6% | 9 qtrs — |
| 93 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.7K -2.6K (-49.5%) | 9.6K -5.8K (-37.8%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD3.06 +16.7% | 21 qtrs — |
| 94 | AMALGAMATED BANK | 2.2K -440.0 (-16.5%) | 8.0K +— (+0.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.20 -50.4% | 19 qtrs — |
| 95 | ROYAL BANK OF CANADA | 1.9K -299.9K (-99.4%) | 7.0K -869.0K (-99.2%) | 0.00% -0.358 pp | 0.00% 0.000 pp | USD2.93 +21.8% | 21 qtrs — |
| 96 | SIMPLEX TRADING, LLC | 1.9K -44.3K (-95.9%) | 6.8K -127.2K (-95.0%) | 0.00% -0.053 pp | 0.00% 0.000 pp | USD3.60 -0.8% | 12 qtrs — |
| 97 | GF FUND MANAGEMENT CO. LTD. | 1.5K -220.0 (-12.5%) | 5.5K +389.0 (+7.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.29 +8.5% | 5 qtrs — |
| 98 | ADVISOR GROUP HOLDINGS, INC. | 1.3K +— (+0.0%) | 4.7K +860.0 (+22.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.40 -33.9% | 19 qtrs — |
| 99 | FEDERATED HERMES, INC. | 1.3K -2.1K (-62.2%) | 4.6K -5.3K (-53.4%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD7.08 -49.6% | 16 qtrs — |
| 100 | OPTIVER HOLDING B.V. | 990.00 +— (+0.0%) | 3.5K +663.0 (+23.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.90 +23.1% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.22% | 637.5K | 0.39% |
| 2 | iShares Micro-Cap ETF IWC | 0.08% | 1.19M | 0.60% |
| 3 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 314.7K | 0.35% |
| 4 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 21.1K | 0.35% |
| 5 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 127.2K | 0.40% |
| 6 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.03% | 20.5K | 0.19% |
| 7 | Avantis U.S. Small Cap Equity ETF AVSC | 0.03% | 753.5K | 0.25% |
| 8 | iShares Biotechnology ETF IBB | 0.02% | 2.23M | 0.44% |
| 9 | iShares Russell 2000 Value ETF IWN | 0.02% | 3.30M | 0.24% |
| 10 | Vanguard Russell 2000 Value ETF VTWV | 0.02% | 260.0K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.08
Neutral
Ratio by volume
2.72
Bullish
Buys
14
Sells
13
Shares acquired
1.70M
Shares disposed
623.9K
Cash buys
—
Cash sales
—
Net activity
+1,074,743
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | Corcoran Andrea | Officer | M-Exempt | A | Common Stock | 60,000 | 1.24 | 74.4K | 823,576 | D | ↗ |
| 2026-02-03 | Sommadossi Jean-Pierre | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 300,000 | 1.24 | 372.0K | 0 | D | ↗ |
| 2026-01-31 | Vavricka John | Officer | M-Exempt | A | Common Stock | 42,083 | 0.00 | — | 94,164 | D | ↗ |
| 2026-01-31 | Sommadossi Jean-Pierre | Director / Officer | M-Exempt | D | Restricted Stock Units | 99,517 | 0.00 | — | 0 | D | ↗ |
| 2026-01-31 | Horga Maria Arantxa | Officer | M-Exempt | A | Common Stock | 51,283 | 0.00 | — | 112,159 | D | ↗ |
| 2026-01-31 | Hammond Janet MJ | Officer | M-Exempt | D | Restricted Stock Units | 11,250 | 0.00 | — | 0 | D | ↗ |
| 2026-01-31 | Foster Wayne | Officer | M-Exempt | D | Restricted Stock Units | 8,000 | 0.00 | — | 0 | D | ↗ |
| 2026-01-31 | Corcoran Andrea | Officer | M-Exempt | A | Common Stock | 54,866 | 0.00 | — | 779,680 | D | ↗ |
| 2025-06-20 | Polsky Bruce | Director | M-Exempt | D | Restricted Stock Units | 29,600 | 0.00 | — | 0 | D | ↗ |
| 2025-06-20 | Murphy Polly A. | Director | M-Exempt | A | Common Stock | 29,600 | 0.00 | — | 86,045 | D | ↗ |
| 2025-06-20 | Lucidi Bruno | Director | M-Exempt | A | Common Stock | 29,600 | 0.00 | — | 112,750 | D | ↗ |
| 2025-06-20 | Duncan Barbara Gayle | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | D | ↗ |
| 2025-06-20 | Berman Howard | Director | A-Award | A | Stock Option (Right to Buy) | 164,800 | 3.25 | 535.6K | 164,800 | D | ↗ |
| 2025-06-20 | BERGER FRANKLIN M | Director | M-Exempt | A | Common Stock | 29,600 | 0.00 | — | 506,497 | D | ↗ |
| 2025-06-20 | Adams Jerome M. | Director | M-Exempt | A | Common Stock | 29,600 | 0.00 | — | 62,750 | D | ↗ |
| 2025-02-20 | Kirsch Arthur S | Director | A-Award | A | Stock Option (Right to Buy) | 164,800 | 3.14 | 517.5K | 164,800 | D | ↗ |
| 2025-01-31 | Vavricka John | Officer | M-Exempt | A | Common Stock | 33,333 | 0.00 | — | 54,848 | D | ↗ |
| 2025-01-31 | Sommadossi Jean-Pierre | Director / Officer | M-Exempt | A | Common Stock | 173,467 | 0.00 | — | 290,024 | D | ↗ |
| 2025-01-31 | Horga Maria Arantxa | Officer | A-Award | A | Restricted Stock Units | 9,750 | 0.00 | — | 9,750 | D | ↗ |
| 2025-01-31 | Hammond Janet MJ | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 3.06 | 612.0K | 200,000 | D | ↗ |
| 2025-01-31 | Foster Wayne | Officer | A-Award | A | Restricted Stock Units | 8,000 | 0.00 | — | 8,000 | D | ↗ |
| 2025-01-31 | Corcoran Andrea | Officer | M-Exempt | A | Common Stock | 44,367 | 0.00 | — | 722,909 | D | ↗ |
| 2025-01-16 | BERGER FRANKLIN M | Director | P-Purchase | A | Common Stock | 10,000 | 3.36 | 33.6K | 476,897 | D | ↗ |
| 2025-01-15 | BERGER FRANKLIN M | Director | P-Purchase | D | Common Stock | 15,000 | 3.19 | 47.9K | 466,897 | D | ↗ |
| 2024-12-10 | BERGER FRANKLIN M | Director | S-Sale | D | Common Stock | 359,606 | 2.85 | 1.02M | 451,897 | D | ↗ |
| 2024-09-19 | Sommadossi Jean-Pierre | Director / Officer | S-Sale | D | Common Stock | 1,841 | 4.00 | 7.4K | 5,866,025 | — | ↗ |
| 2024-09-18 | Sommadossi Jean-Pierre | Director / Officer | S-Sale | D | Common Stock | 22,187 | 4.03 | 89.5K | 5,867,866 | — | ↗ |
| 2024-09-17 | Sommadossi Jean-Pierre | Director / Officer | S-Sale | D | Common Stock | 33,941 | 4.05 | 137.3K | 5,890,053 | — | ↗ |
| 2024-06-21 | Polsky Bruce | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-21 | Murphy Polly A. | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-21 | Lucidi Bruno | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-21 | Duncan Barbara Gayle | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-21 | BERGER FRANKLIN M | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-21 | Adams Jerome M. | Director | A-Award | A | Restricted Stock Units | 29,600 | 0.00 | — | 29,600 | — | ↗ |
| 2024-06-20 | Polsky Bruce | Director | S-Sale | D | Common Stock | 17,544 | 3.49 | 61.1K | 65,606 | — | ↗ |
| 2024-06-16 | Polsky Bruce | Director | M-Exempt | A | Common Stock | 33,150 | 0.00 | — | 83,150 | — | ↗ |
| 2024-06-16 | Murphy Polly A. | Director | M-Exempt | D | Restricted Stock Units | 33,150 | 0.00 | — | 0 | — | ↗ |
| 2024-06-16 | Lucidi Bruno | Director | M-Exempt | A | Common Stock | 33,150 | 0.00 | — | 83,150 | — | ↗ |
| 2024-06-16 | Duncan Barbara Gayle | Director | M-Exempt | A | Common Stock | 33,150 | 0.00 | — | 33,150 | — | ↗ |
| 2024-06-16 | BERGER FRANKLIN M | Director | M-Exempt | D | Restricted Stock Units | 33,150 | 0.00 | — | 0 | — | ↗ |
| 2024-06-16 | Adams Jerome M. | Director | M-Exempt | D | Restricted Stock Units | 33,150 | 0.00 | — | 0 | — | ↗ |
| 2024-06-05 | Sommadossi Jean-Pierre | Director / Officer | S-Sale | D | Common Stock | 1,006 | 4.00 | 4.0K | 5,923,994 | — | ↗ |
| 2024-02-01 | Vavricka John | Officer | S-Sale | D | Common Stock | 11,819 | 3.84 | 45.4K | 21,515 | — | ↗ |
| 2024-02-01 | Sommadossi Jean-Pierre | Director / Officer | S-Sale | D | Common Stock | 56,910 | 3.85 | 218.8K | 116,557 | — | ↗ |
| 2024-02-01 | Horga Maria Arantxa | Officer | S-Sale | D | Common Stock | 15,870 | 3.84 | 61.0K | 25,664 | — | ↗ |
| 2024-02-01 | Hammond Janet MJ | Officer | S-Sale | D | Common Stock | 14,029 | 3.84 | 53.9K | 35,362 | — | ↗ |
| 2024-02-01 | Foster Wayne | Officer | S-Sale | D | Common Stock | 12,477 | 3.84 | 47.9K | 20,857 | — | ↗ |
| 2024-02-01 | Corcoran Andrea | Officer | S-Sale | D | Common Stock | 15,843 | 3.84 | 60.9K | 670,208 | — | ↗ |
| 2024-01-31 | Vavricka John | Officer | M-Exempt | A | Common Stock | 33,334 | 0.00 | — | 33,334 | — | ↗ |
| 2024-01-31 | Sommadossi Jean-Pierre | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 448,000 | 4.16 | 1.86M | 448,000 | — | ↗ |
| 2024-01-31 | Horga Maria Arantxa | Officer | M-Exempt | A | Common Stock | 41,534 | 0.00 | — | 41,534 | — | ↗ |
| 2024-01-31 | Hammond Janet MJ | Officer | M-Exempt | A | Common Stock | 46,800 | 0.00 | — | 49,391 | — | ↗ |
| 2024-01-31 | Foster Wayne | Officer | M-Exempt | A | Common Stock | 33,334 | 0.00 | — | 33,334 | — | ↗ |
| 2024-01-31 | Corcoran Andrea | Officer | M-Exempt | A | Common Stock | 44,367 | 0.00 | — | 686,051 | — | ↗ |
| 2023-06-16 | Polsky Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 46,750 | 4.12 | 192.6K | 46,750 | — | ↗ |
| 2023-06-16 | Murphy Polly A. | Director | A-Award | A | Stock Option (Right to Buy) | 46,750 | 4.12 | 192.6K | 46,750 | — | ↗ |
| 2023-06-16 | Lucidi Bruno | Director | A-Award | A | Stock Option (Right to Buy) | 46,750 | 4.12 | 192.6K | 46,750 | — | ↗ |
| 2023-06-16 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 46,750 | 4.12 | 192.6K | 46,750 | — | ↗ |
| 2023-06-16 | BERGER FRANKLIN M | Director | A-Award | A | Stock Option (Right to Buy) | 46,750 | 4.12 | 192.6K | 46,750 | — | ↗ |
| 2023-06-16 | Adams Jerome M. | Director | A-Award | A | Restricted Stock Units | 33,150 | 0.00 | — | 33,150 | — | ↗ |
| 2023-01-31 | Vavricka John | Officer | A-Award | A | Restricted Stock Units | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-31 | Sommadossi Jean-Pierre | Director / Officer | A-Award | A | Restricted Stock Units | 520,400 | 0.00 | — | 520,400 | — | ↗ |
| 2023-01-31 | Horga Maria Arantxa | Officer | A-Award | A | Restricted Stock Units | 124,600 | 0.00 | — | 124,600 | — | ↗ |
| 2023-01-31 | Hammond Janet MJ | Officer | A-Award | A | Restricted Stock Units | 140,400 | 0.00 | — | 140,400 | — | ↗ |
| 2023-01-31 | Foster Wayne | Officer | A-Award | A | Restricted Stock Units | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2023-01-31 | Corcoran Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 186,300 | 4.63 | 862.6K | 186,300 | — | ↗ |
| 2022-11-14 | BERGER FRANKLIN M | Director | S-Sale | D | Common Stock | 16,166 | 5.16 | 83.4K | 778,353 | — | ↗ |
| 2022-11-11 | BERGER FRANKLIN M | Director | S-Sale | D | Common Stock | 25,500 | 5.15 | 131.3K | 794,519 | — | ↗ |
| 2022-06-17 | Polsky Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 0.00 | — | 61,264 | — | ↗ |
| 2022-06-17 | Murphy Polly A. | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 0.00 | — | 61,264 | — | ↗ |
| 2022-06-17 | Lucidi Bruno | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 0.00 | — | 61,264 | — | ↗ |
| 2022-06-17 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 0.00 | — | 61,264 | — | ↗ |
| 2022-06-17 | BERGER FRANKLIN M | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 6.50 | 398.2K | 61,264 | — | ↗ |
| 2022-06-17 | Adams Jerome M. | Director | A-Award | A | Stock Option (Right to Buy) | 61,264 | 0.00 | — | 61,264 | — | ↗ |
| 2022-01-31 | Vavricka John | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 7.14 | 963.9K | 135,000 | — | ↗ |
| 2022-01-31 | Sommadossi Jean-Pierre | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 378,033 | 7.14 | 2.70M | 378,033 | — | ↗ |
| 2022-01-31 | Horga Maria Arantxa | Officer | A-Award | A | Stock Option (Right to Buy) | 170,000 | 7.14 | 1.21M | 170,000 | — | ↗ |
| 2022-01-31 | Hammond Janet MJ | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 7.14 | 1.36M | 190,000 | — | ↗ |
| 2022-01-31 | Foster Wayne | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 7.14 | 856.8K | 120,000 | — | ↗ |
| 2022-01-31 | Corcoran Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 181,000 | 7.14 | 1.29M | 181,000 | — | ↗ |
| 2021-12-20 | Murphy Polly A. | Director | P-Purchase | A | Common Stock | 12,000 | 8.57 | 102.8K | 23,295 | — | ↗ |
| 2021-06-18 | Polsky Bruce | Director | A-Award | A | Stock Option (Right to Buy) | 34,025 | 23.39 | 795.8K | 34,025 | — | ↗ |
| 2021-06-18 | Murphy Polly A. | Director | A-Award | A | Stock Option (Right to Buy) | 34,025 | 23.39 | 795.8K | 34,025 | — | ↗ |
| 2021-06-18 | Lucidi Bruno | Director | A-Award | A | Stock Option (Right to Buy) | 34,025 | 23.39 | 795.8K | 34,025 | — | ↗ |
| 2021-06-18 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 34,025 | 23.39 | 795.8K | 34,025 | — | ↗ |
| 2021-06-18 | BERGER FRANKLIN M | Director | A-Award | A | Stock Option (Right to Buy) | 34,025 | 23.39 | 795.8K | 34,025 | — | ↗ |
| 2021-05-18 | Adams Jerome M. | Director | A-Award | A | Stock Option (Right to Buy) | 56,670 | 23.43 | 1.33M | 56,670 | — | ↗ |
| 2021-01-29 | Vavricka John | Officer | A-Award | A | Stock Option (Right to Buy) | 117,300 | 73.00 | 8.56M | 117,300 | — | ↗ |
| 2021-01-29 | Sommadossi Jean-Pierre | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 640,000 | 73.00 | 46.72M | 640,000 | — | ↗ |
| 2021-01-29 | Horga Maria Arantxa | Officer | A-Award | A | Stock Option (Right to Buy) | 145,500 | 73.00 | 10.62M | 145,500 | — | ↗ |
| 2021-01-29 | Hammond Janet MJ | Officer | A-Award | A | Stock Option (Right to Buy) | 160,050 | 73.00 | 11.68M | 160,050 | — | ↗ |
| 2021-01-29 | Foster Wayne | Officer | A-Award | A | Stock Option (Right to Buy) | 71,750 | 73.00 | 5.24M | 71,750 | — | ↗ |
| 2021-01-29 | Corcoran Andrea | Officer | A-Award | A | Stock Option (Right to Buy) | 148,850 | 73.00 | 10.87M | 148,850 | — | ↗ |
| 2020-11-03 | Vavricka John | Officer | C-Conversion | A | Common Stock | 82,508 | 0.00 | — | 82,508 | — | ↗ |
| 2020-11-03 | Sommadossi Jean-Pierre | Director / Officer | C-Conversion | A | Common Stock | 750,000 | 0.00 | — | 5,925,000 | — | ↗ |
| 2020-11-03 | Rock Springs Capital Management LP | 10% Owner | C-Conversion | A | Common Stock | 1,412,016 | 0.00 | — | 1,412,016 | — | ↗ |
| 2020-11-03 | Murphy Polly A. | Director | C-Conversion | D | Series D Convertible Preferred Stock | 7,122 | 0.00 | — | 0 | — | ↗ |
| 2020-11-03 | Hack Andrew A. F. | Director | P-Purchase | A | Common Stock | 250,000 | 24.00 | 6.00M | 5,615,659 | — | ↗ |
| 2020-11-03 | Cormorant Asset Management, LP | — | C-Conversion | A | Common Stock | 6,411,355 | 0.00 | — | 6,411,355 | — | ↗ |
| 2020-11-03 | Corcoran Andrea | Officer | C-Conversion | D | Series A Convertible Preferred Stock | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2020-11-03 | Chu Chung K. | 10% Owner | C-Conversion | D | Series B Convertible Preferred Stock | 33,003 | 0.00 | — | 0 | — | ↗ |
| 2020-11-03 | BERGER FRANKLIN M | Director | C-Conversion | A | Common Stock | 759,606 | 0.00 | — | 778,353 | — | ↗ |
| 2020-10-29 | Vavricka John | Officer | — | I | Series B Convertible Preferred Stock | 82,508 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Sommadossi Jean-Pierre | Director / Officer / 10% Owner | — | D | Stock Option (Right to Buy) | 185,000 | 1.53 | 283.1K | 0 | — | ↗ |
| 2020-10-29 | Rock Springs Capital Management LP | 10% Owner | — | I | Series D Convertible Preferred Stock | 178,063 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Polsky Bruce | Director | — | D | Stock Option (Right to Buy) | 50,000 | 1.43 | 71.5K | 0 | — | ↗ |
| 2020-10-29 | Murphy Polly A. | Director | — | D | Stock Option (Right to Buy) | 80,000 | 6.84 | 547.2K | 0 | — | ↗ |
| 2020-10-29 | Lucidi Bruno | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 24.00 | 1.92M | 80,000 | — | ↗ |
| 2020-10-29 | Horga Maria Arantxa | Officer | — | D | Stock Option (Right to Buy) | 350,000 | 6.85 | 2.40M | 0 | — | ↗ |
| 2020-10-29 | Hammond Janet MJ | Officer | — | D | Stock Option (Right to Buy) | 650,000 | 6.84 | 4.45M | 0 | — | ↗ |
| 2020-10-29 | Hack Andrew A. F. | Director | — | I | Series D-1 Convertible Preferred Stock | 1,982,469 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Foster Wayne | Officer | — | D | Stock Option (Right to Buy) | 125,000 | 6.83 | 853.8K | 0 | — | ↗ |
| 2020-10-29 | Duncan Barbara Gayle | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 24.00 | 1.92M | 80,000 | — | ↗ |
| 2020-10-29 | Cormorant Asset Management, LP | 10% Owner | — | I | Series B Convertible Preferred Stock | 1,650,165 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Corcoran Andrea | Officer | — | D | Series A Convertible Preferred Stock | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | Chu Chung K. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2020-10-29 | Cheng Isaac | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-29 | BERGER FRANKLIN M | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 24.00 | 1.92M | 80,000 | — | ↗ |
| 2018-02-13 | LESCHLY JAN | Director / 10% Owner | A-Award | A | Common Stock | 30,793,670 | 0.82 | 25.25M | 30,793,670 | — | ↗ |
| 2017-05-18 | Dunne Michael W. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.49 | 9.8K | 75,000 | — | ↗ |
| 2017-05-18 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.49 | 9.8K | 105,000 | — | ↗ |
| 2017-05-18 | ANIDO ARMANDO | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.49 | 9.8K | 75,000 | — | ↗ |
| 2017-04-03 | PATTI JOSEPH M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.66 | 426.4K | 2,113,304 | — | ↗ |
| 2017-04-03 | COLONNESE MARK P | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 0.66 | 262.4K | 775,000 | — | ↗ |
| 2016-08-11 | PATTI JOSEPH M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 380,000 | 1.30 | 494.0K | 1,478,929 | — | ↗ |
| 2016-07-27 | COLONNESE MARK P | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.34 | 201.0K | 375,000 | — | ↗ |
| 2016-05-12 | Dunne Michael W. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.50 | 30.0K | 20,000 | — | ↗ |
| 2016-05-12 | DOUGHERTY MICHAEL R | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.50 | 30.0K | 20,000 | — | ↗ |
| 2016-05-12 | ANIDO ARMANDO | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.50 | 30.0K | 20,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
79.67M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jean-Pierre Sommadossi, PhD President, Chief Executive Officer and Chairman of the Board | 703.5K | — | 1.32M | 962.4K | 422.1K | — | 3.40M | 66.93% | ↗ |
| 2 | 2025 | Janet Hammond, MD, PhD Chief Development Officer | 590.9K | — | 459.0K | 437.4K | 265.9K | 14.0K | 1.77M | 50.73% | ↗ |
| 3 | 2025 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 549.5K | — | 442.2K | 437.4K | 247.3K | 14.0K | 1.69M | 52.03% | ↗ |
| 4 | 2025 | Maria Arantxa Horga, MD Chief Medical Officer | 523.6K | — | 425.0K | 421.7K | 209.5K | 14.0K | 1.59M | 53.13% | ↗ |
| 5 | 2025 | John Vavricka Chief Commercial Officer | 443.2K | — | 292.8K | 290.5K | 177.3K | 14.0K | 1.22M | 47.90% | ↗ |
| 6 | 2024 | Jean-Pierre Sommadossi, PhD President, Chief Executive Officer and Chairman of the Board | 703.5K | — | 1.79M | 1.37M | 337.7K | — | 4.20M | 75.22% | ↗ |
| 7 | 2024 | Janet Hammond, MD, PhD Chief Development Officer | 573.7K | — | 675.2K | 689.9K | 206.5K | 13.8K | 2.16M | 63.22% | ↗ |
| 8 | 2024 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 533.5K | — | 601.1K | 612.7K | 170.7K | 13.8K | 1.93M | 62.83% | ↗ |
| 9 | 2024 | Maria Arantxa Horga, MD Chief Medical Officer | 508.4K | — | 577.8K | 590.6K | 162.7K | 13.8K | 1.85M | 63.05% | ↗ |
| 10 | 2024 | John Vavricka Chief Commercial Officer | 430.3K | — | 398.1K | 406.8K | 137.7K | 13.8K | 1.39M | 58.05% | ↗ |
| 11 | 2023 | Jean-Pierre Sommadossi, Ph.D. President, Chief Executive Officer and Chairman of the Board | 683.0K | — | 2.41M | 2.47M | 358.6K | — | 5.93M | 82.42% | ↗ |
| 12 | 2023 | Jean-Pierre Sommadossi, PhD President, Chief Executive Officer and Chairman of the Board | 683.0K | — | 2.41M | 2.47M | 358.6K | — | 5.93M | 82.42% | ↗ |
| 13 | 2023 | Janet Hammond, M.D., Ph.D. Chief Development Officer | 557.0K | — | 650.1K | 667.8K | 219.3K | 13.2K | 2.11M | 62.54% | ↗ |
| 14 | 2023 | Janet Hammond, MD, PhD Chief Development Officer | 557.0K | — | 650.1K | 667.8K | 219.3K | 13.2K | 2.11M | 62.54% | ↗ |
| 15 | 2023 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 518.0K | — | 616.3K | 632.8K | 181.3K | 13.2K | 1.96M | 63.68% | ↗ |
| 16 | 2023 | Maria Arantxa Horga, M.D. Chief Medical Officer | 493.6K | — | 576.9K | 592.7K | 172.8K | 13.2K | 1.85M | 63.25% | ↗ |
| 17 | 2023 | Maria Arantxa Horga, MD Chief Medical Officer | 493.6K | — | 576.9K | 592.7K | 172.8K | 13.2K | 1.85M | 63.25% | ↗ |
| 18 | 2023 | Wayne Foster Executive Vice President, Chief Accounting Officer | 420.2K | — | 463.0K | 475.5K | 147.1K | 13.2K | 1.52M | 61.79% | ↗ |
| 19 | 2023 | John Vavricka Chief Commercial Officer | 417.7K | — | 463.0K | 475.5K | 146.2K | 13.2K | 1.52M | 61.92% | ↗ |
| 20 | 2022 | Jean-Pierre Sommadossi, Ph.D. President, Chief Executive Officer and Chairman of the Board | 650.0K | — | 2.84M | 1.94M | 448.5K | — | 5.88M | 81.31% | ↗ |
| 21 | 2022 | Jean-Pierre Sommadossi, PhD President, Chief Executive Officer and Chairman of the Board | 650.0K | — | 2.84M | 1.94M | 448.5K | — | 5.88M | 81.31% | ↗ |
| 22 | 2022 | Janet Hammond, M.D., Ph.D. Chief Development Officer | 530.5K | — | 321.3K | 973.7K | 274.5K | 12.2K | 2.11M | 61.31% | ↗ |
| 23 | 2022 | Janet Hammond, MD, PhD Chief Development Officer | 530.5K | — | 321.3K | 973.7K | 274.5K | 12.2K | 2.11M | 61.31% | ↗ |
| 24 | 2022 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 493.3K | — | 299.9K | 927.6K | 226.9K | 12.2K | 1.96M | 62.63% | ↗ |
| 25 | 2022 | Andrea Corcoran Chief Financial Officer, | 493.3K | — | 299.9K | 927.6K | 226.9K | 12.2K | 1.96M | 62.63% | ↗ |
| 26 | 2022 | Maria Arantxa Horga, MD Chief Medical Officer | 470.1K | — | 278.5K | 871.2K | 216.2K | 9.5K | 1.85M | 62.29% | ↗ |
| 27 | 2022 | Maria Arantxa Horga, M.D. Chief Medical Officer | 470.1K | — | 278.5K | 871.2K | 216.2K | 9.5K | 1.85M | 62.29% | ↗ |
| 28 | 2022 | John Vavricka Chief Commercial Officer | 397.8K | — | 249.9K | 691.8K | 171.1K | 12.2K | 1.52M | 61.84% | ↗ |
| 29 | 2021 | Jean-Pierre Sommadossi, Ph.D. President, Chief Executive Officer and Chairman of the Board | 650.0K | — | — | 33.12M | 331.5K | — | 34.10M | 97.12% | ↗ |
| 30 | 2021 | Janet Hammond, M.D., Ph.D. Chief Development Officer | 515.0K | — | — | 8.28M | 197.0K | 11.6K | 9.01M | 91.97% | ↗ |
| 31 | 2021 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 479.0K | — | — | 7.70M | 162.8K | 11.6K | 8.36M | 92.18% | ↗ |
| 32 | 2021 | Andrea Corcoran Chief Financial Officer, | 479.0K | — | — | 7.70M | 162.8K | 11.6K | 8.36M | 92.18% | ↗ |
| 33 | 2021 | Maria Arantxa Horga, M.D. Chief Medical Officer | 452.0K | — | — | 7.53M | 142.4K | 11.6K | 8.14M | 92.55% | ↗ |
| 34 | 2021 | John Vavricka Chief Commercial Officer | 386.3K | — | — | 6.07M | 131.3K | 10.9K | 6.60M | 91.99% | ↗ |
| 35 | 2020 | Janet Hammond, M.D., Ph.D. Chief Development Officer | 197.1K | 431.2K | — | 3.30M | — | 100.0K | 4.03M | 81.93% | ↗ |
| 36 | 2020 | Jean-Pierre Sommadossi, Ph.D. President, Chief Executive Officer and Chairman of the Board | 436.9K | 466.1K | — | 1.98M | — | — | 2.89M | 68.72% | ↗ |
| 37 | 2020 | Nathanial Brown, M.D. Former Chief Medical Officer | 197.5K | 57.0K | — | 2.26M | — | 85.0K | 2.60M | 86.93% | ↗ |
| 38 | 2020 | Maria Arantxa Horga, M.D. Chief Medical Officer | 142.6K | 225.0K | — | 1.78M | — | — | 2.15M | 82.90% | ↗ |
| 39 | 2020 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 465.0K | 279.0K | — | 744.0K | — | — | 1.49M | 50.00% | ↗ |
| 40 | 2019 | Jean-Pierre Sommadossi, Ph.D. President, Chief Executive Officer and Chairman of the Board | 400.0K | 160.0K | — | 251.1K | — | — | 811.1K | 30.96% | ↗ |
| 41 | 2019 | Andrea Corcoran Chief Financial Officer, Executive Vice President, Legal | 290.0K | 75.0K | — | 75.3K | — | — | 440.3K | 17.11% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jean-Pierre Sommadossi | Founder, Chairman, Chief Executive Officer & President | 1M | — |
| Janet J. Hammond | Chief Development Officer | 870.8K | — |
| Andrea J. Corcoran | Chief Financial Officer, Executive Vice President of Legal & Secretary | 810.8K | female |
| Maria Arantxa Horga | Chief Medical Officer | 747.1K | — |
| John F. Vavricka | Chief Commercial Officer | 634.4K | male |
| Wayne Foster | Executive Vice President of Finance & Chief Accounting Officer | 580.5K | male |
| Qi Huang | Senior Vice President of Virology | — | female |
| Adel Moussa | Executive Vice President of Chemistry | — | male |
| Xiao-Jian Zhou | Executive Vice President of Early Stage Development | — | male |
| Jayanthi Wolf | Executive Vice President of Regulatory Affairs | — | — |
| Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications | — | female |
| Keith Pietropaolo | Executive Vice President of Clinical Sciences & Project Management | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVIR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
